LinkedIn emplea cookies para mejorar la funcionalidad y el rendimiento de nuestro sitio web, así como para ofrecer publicidad relevante. Si continúas navegando por ese sitio web, aceptas el uso de cookies. Consulta nuestras Condiciones de uso y nuestra Política de privacidad para más información.
LinkedIn emplea cookies para mejorar la funcionalidad y el rendimiento de nuestro sitio web, así como para ofrecer publicidad relevante. Si continúas navegando por ese sitio web, aceptas el uso de cookies. Consulta nuestra Política de privacidad y nuestras Condiciones de uso para más información.
Guide to Pharmacology Poster - ELIXIR All Hands 2020
3. GtoPdb Coronavirus Information
2. Current database content
Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK. 2
School of Life Sciences, University of Nottingham Medical School, Nottingham, UK. 3
Experimental Medicine and
Immunotherapeutics, University of Cambridge, Cambridge. 4
Spedding Research Solutions SAS, Le Vesinet, France. * The International Union of Basic and Clinical Pharmacology Committee on
Receptor Nomenclature and Drug Classification.
The IUPHAR/BPS Guide to PHARMACOLOGY
The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb) is an open, expert-driven database of
pharmacological targets and the substances that act on them . It is a joint initiative between
the British Pharmacological Society (BPS) and the International Union of Basic and Clinical
Pharmacology (IUPHAR), which aims to cover the human targets of licensed drugs and other
likely targets of future therapeutics.
The information is presented at two levels:
1. Overviews of the key properties, selective ligands and further reading for a wide range of
human biological targets, which forms the basis for the Concise Guide to PHARMACOLOGY
2. Detailed pharmacological, functional and clinical information for a subset of important
All data are curated from the primary literature by an international network of 500 experts in
96 subcommittees of the IUPHAR Committee on Receptor Nomenclature and Drug
~1,800 established or potential data-supported drug targets
~1,100 additional related proteins
Across several target classes: GPCRs, NHRs, Enzymes, Ion-Channels, Catalytic Receptors,
Transporter and other protein targets
1. Armstrong JF, et al. (2020). Nucl. Acids Res. 48 (Issue D1): D1006-D1021.
2. Alexander SPH, et al. (2019). Br J Pharmacol. 176 (Suppl 1): S1-S493.
3. Alexander SPH, et al. (2020). Br J Pharmacol. Online ahead of print. DOI: 10.1111/bph.15094
4. Gaulton A, et al. (2017). Nucl. Acids Res. 45 (Database Issue): D945-D954.
5. Harding SD, et al. (2020). Immunology. 160(1): 10-23.
6. Medicines for Malaria Venture https://www.mmv.org/
In addition, for a “how-to” guide on using GtoPdb see: Sharman JL, et al. (2018) Curr Protoc Bioinformatics. 61: 1.34.1-1.34.46.
5. IUPHAR Guide to Immunopharmacology
Launched in October 2018, the Wellcome Trust-funded IUPHAR Guide to Immunopharmacology
(GtoImmuPdb; www.guidetoimmunopharmacology.org) extends the information stored about
drug targets by associating them with processes, cell types and disease of relevance to
Providing a knowledge base that, for the first time, connects immunology with pharmacology .
Simon D. Harding1
, Jane F. Armstrong1
, Elena Faccenda1
, Adam J. Pawson1
, Christopher Southan1
, Stephen P.H. Alexander2
Anthony P. Davenport3
, Michael Spedding4
, Jamie A. Davies1
6. IUPHAR/MMV Guide to Malaria Pharmacology
www.guidetopharmacology.org firstname.lastname@example.org @GuidetoPHARM
4. Comparing ligand affinity across species
Ligand activity graphs provide a quick way to visualise affinity at different targets and across
species. Box plots (Fig. 2A) summarise standardised activity data from GtoPdb and ChEMBL .
Individual data points, assay details and references are provided in an accompanying table (Fig.
Figure 2. Chart and table showing palosuran activity at human and rat UT receptors.
7. New features and accessing GtoPbd data
New website features
• Explicit links between ligands/drugs and clinical trials on ligand summary pages
• New tag for WHO Essential Medicines
• External links added to European PMC
Accessing GtoPdb Data can be done in a number of ways:
• Lists of targets, ligands and interactions in CSV format
• REST web services for computational access to data in JSON format
• SQL database dump files
• Interaction data are now available in RDF format for semantic integration
• BioSchemas semantic mark-up across ligand, target and coronavirus pages
~10,000 ligands, over 7,000 with quantitative interaction data
Includes experimental compounds, labelled ligands, antibodies,
peptides, natural products and inorganic chemicals
> 1,450 approved drugs, >950 with quantitative interaction
540 targets and over 1,000 ligands of relevance to
700 associations between ligands and disease
3,000 target to immuno process associations
300 target to cell type associations
This expert curation seeks to bring the most valuable
pharmacological data into the hands of immunology
researchers, facilitating the crossover of their research
into drug discovery and therapeutics
We especially thank all contributors, collaborators and NC-IUPHAR members
Since October 2017, collaboration between IUPHAR and Medicines for Malaria
Venture (MMV)  to curate antimalarial compounds and Plasmodium molecular
targets for approved drugs.
To provide optimised access to GtoPdb data for the malaria research community.
• Provides a unique access point to the
antimalarial information in our expert-curated
• Designed in consultation with malaria
researchers to provide tailored routes into
browsing the antimalarial data
Currently there are 80 antimalarial ligands
curated in the database, covering 33 Plasmodium
We submit all our curated antimalarial
compounds, that include approved drugs, clinical
candidates and research leads, to PubChem where
they acquire GtoPdb-specific Substance Identifiers
(SIDs). These currently merge into 57 Compound
Identifiers (CIDs) that are fully searchable in
Our latest database report can be found here:Our latest database report can be found here: http://ow.ly/Qld650zXKWB Slideshare:
Given the novelty of SARS-CoV-2 infection (COVID-19), and the lack of proven therapies, a wide
variety of strategies are being employed to combat this worldwide epidemic. Many of these
emerging strategies rely on repurposing existing drugs, and others are completely new, but all
rely on existing scientific evidence of mechanistic approaches that are effective against either
similar viral infections or the serious symptoms that are caused by COVID-19.
All of these tactics are intended to mitigate
against COVID-19 and provide a window
during which vaccine development can
GtoPdb collates information on many of the
pharmacological strategies and tactics being
considered. It also provide links to key
publications and other useful resources
related to SARS-CoV-2 and COVID-19.
We have also recently published “A Rational Roadmap for SARS-CoV-2/COVID-19
Pharmacotherapeutic Research and Development”  in which we identify opportunities for
drug discovery in the treatment of COVID 19 and in so doing, provide a rational roadmap‐
whereby pharmacology and pharmacologists can mitigate against the global pandemic.